Compare JetBlue Airways Corporation (JBLU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs TG Therapeutics Inc — how do they compare? JetBlue Airways Corporation trades at $5.15 (market cap $1.99B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 4.2× JetBlue Airways Corporation's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| JBLU | TGTX | |
|---|---|---|
Market Cap | $1.99B | $8.26B |
Sector | Industrials | Health |
52-Week High | $6.46 | $59.06 |
52-Week Low | $4.03 | $26.39 |
Enterprise Value | $9.15B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.35, down 1.29% on the day, with mixed technical signals showing a neutral overall bias. The company faces fundamental challenges with negative profitability metrics, including a -7.78% net income margin and -33.51% ROE, despite reasonable valuation ratios like P/S of 0.22. Recent developments include securing Spirit Airlines' LaGuardia Airport slots and launching new payment partnerships, providing potential operational catalysts amid ongoing losses.
The outlook remains challenging with persistent net losses and high debt levels, though strategic expansions and new financing options offer growth potential. Key risks include fuel cost volatility and competitive pressures, while analyst sentiment is cautious with a $5.12 consensus target suggesting limited upside from current levels.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
